Plus   Neg

Merck To Acquire Pandion Therapeutics - Quick Facts

Merck (MRK) has agreed to acquire Pandion Therapeutics, Inc. (PAND), a clinical-stage biotechnology company developing therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion.

Merck, through a unit, will initiate a tender offer to acquire all outstanding shares of Pandion. Upon the successful completion of the tender offer, Merck's acquisition unit will be merged into Pandion. The deal is expected to close in the first half of 2021.

PT101, the lead candidate of Pandion, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases. PT101 had completed a phase 1a clinical trial, which achieved its primary objective of safety and tolerability.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT